Inhibition of tRNA fragments dysregulated in human mTLE exacerbates pathology and seizure activity
Clinical Scorecard: Suppression of Dysregulated tRNA Fragments in Human mTLE Aggravates Seizure Activity and Pathological Outcomes
At a Glance
Category Detail
Condition Mesial Temporal Lobe Epilepsy (mTLE) Key Mechanisms Dysregulation of tRNA fragments (tRFs) affects seizure activity and glial changes. Target Population Individuals with mesial temporal lobe epilepsy, particularly those with pharmaco-resistant seizures. Care Setting Neurological research and clinical settings focusing on epilepsy treatment.
Key Highlights
Approximately one-third of mTLE patients develop pharmaco-resistance against anti-seizure drugs. Dysregulated tRNA fragments were identified in mTLE brain tissue compared to controls. Inhibition of specific tRNA fragments increased seizure frequency in a mouse model. tRNA fragments can influence gene expression and neuronal activity. Patients with uncontrolled seizures are at increased risk for mood disorders and cognitive problems. Guideline-Based Recommendations
Diagnosis
Diagnosis of mTLE involves clinical assessment and may include imaging studies. Management
Consider resective surgery for eligible patients with refractory mTLE. Monitoring & Follow-up
Monitor seizure frequency and associated cognitive and mood changes in mTLE patients. Risks
Uncontrolled seizures can lead to mood disorders, cognitive issues, and increased mortality risk. Patient & Prescribing Data
Patients with mesial temporal lobe epilepsy, particularly those resistant to standard treatments.
Emerging research suggests targeting tRNA fragments may offer new therapeutic avenues.
Clinical Best Practices
Assess the potential for surgical intervention in patients with refractory mTLE. Evaluate the role of small non-coding RNAs in the pathophysiology of epilepsy. Related Resources & Content
